GOODWILL IPRANDD AND OTHER INTANGIBLE ASSETS, NET (Tables)

9 Months Ended

Sep. 30, 2013

GOODWILL, IPR&D AND OTHER INTANGIBLE ASSETS, NET

Schedule of the Company's goodwill balance

	Goodwill
	(in thousands)
Beginning balance as of December 31, 2012	$	114,130
Goodwill acquired	159,442
Ending balance as of September 30, 2013	$	273,572

Schedule of carrying value of the Company's IPR&D assets

	September 30, 2013		December 31, 2012
	(in thousands)
Development and potential commercialization of:
Tedizolid phosphate	$	659,000	$	—
Bevenopran	78,700		78,700
Ceftolozane/tazobactam for HABP and VABP	174,000		174,000
Ceftolozane/tazobactam for cUTI and cIAI	20,000		20,000
Total IPR&D	$	931,700	$	272,700

Schedule of other intangible assets, net

		September 30, 2013			December 31, 2012
		(in thousands)
Patents		$	2,627		$	2,627
Acquired technology rights		191,800			191,800
		194,427			194,427
Less:	accumulated amortization — patents	(2,477		)	(2,431		)
	accumulated amortization — acquired technology rights	(54,539		)	(39,166		)
Other intangible assets, net		$	137,411		$	152,830

Schedule of estimated aggregate amortization of intangible assets

	(in thousands)
Remainder of 2013	$	5,182
2014	20,729
2015	20,729
2016	19,449
2017	18,210
2018 and thereafter	53,112
Total	$	137,411